KNSA (STOCKS)
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$46.266000
-0.814000 (-1.73%)
Prev close: $47.080000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Sanj K. Patel
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,616.68M
- Employees
- 315
- P/E (TTM)
- 63.02
- P/B (TTM)
- 6.33
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.17 | $0.38 | -0.2119 | -55.49% |
|
Sep 2025 (Q3)
|
$0.23 | $0.33 | -0.0998 | -30.26% |
|
Jun 2025 (Q2)
|
$0.23 | $0.19 | +0.0442 | +23.79% |
|
Mar 2025 (Q1)
|
$0.11 | $0.04 | +0.0672 | +157.01% |
Financial Statements
| Revenues | $677.56M |
| Benefits Costs and Expenses | $588.70M |
| Cost Of Revenue | $77.67M |
| Costs And Expenses | $588.70M |
| Gross Profit | $599.89M |
| Operating Expenses | $522.67M |
| Selling, General, and Administrative Expenses | $196.27M |
| Depreciation and Amortization | $1.55M |
| Research and Development | $96.85M |
| Other Operating Expenses | $227.99M |
| Operating Income/Loss | $77.22M |
| Income/Loss From Continuing Operations After Tax | $59.01M |
| Income/Loss From Continuing Operations Before Tax | $88.87M |
| Income Tax Expense/Benefit | $29.86M |
| Income Tax Expense/Benefit, Current | $16.86M |
| Income Tax Expense/Benefit, Deferred | $13.00M |
| Net Income/Loss | $59.01M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $59.01M |
| Net Income/Loss Available To Common Stockholders, Basic | $59.01M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.80 |
| Diluted Earnings Per Share | $0.75 |
| Basic Average Shares | 74,200,924 |
| Diluted Average Shares | 78,979,030 |
| Assets | $763.63M |
| Current Assets | $527.18M |
| Cash | $414.07M |
| Inventory | $54.90M |
| Other Current Assets | $58.21M |
| Noncurrent Assets | $236.46M |
| Fixed Assets | $1.94M |
| Other Non-current Assets | $234.51M |
| Liabilities | $196.03M |
| Current Liabilities | $139.18M |
| Accounts Payable | $2.03M |
| Wages | $6.63M |
| Other Current Liabilities | $130.53M |
| Noncurrent Liabilities | $56.84M |
| Equity | $567.61M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $567.61M |
| Liabilities And Equity | $763.63M |
| Net Cash Flow From Operating Activities | $137.99M |
| Net Cash Flow From Operating Activities, Continuing | $137.99M |
| Net Cash Flow From Investing Activities | -$188.99M |
| Net Cash Flow From Investing Activities, Continuing | -$188.99M |
| Net Cash Flow From Financing Activities | $33.02M |
| Net Cash Flow From Financing Activities, Continuing | $33.02M |
| Net Cash Flow | -$17.99M |
| Net Cash Flow, Continuing | -$17.99M |
| Comprehensive Income/Loss | $59.14M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $59.14M |
| Other Comprehensive Income/Loss | $138.00K |
| Other Comprehensive Income/Loss Attributable To Parent | $138.00K |